Clinical Trial: Implementation of Standardized Early Identification and Diagnosis for Transthyretin Amyloidosis (ATTR) in High-Risk Populations

U.S., Jan. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07338942) titled 'Implementation of Standardized Early Identification and Diagnosis for Transthyretin Amyloidosis (ATTR) in High-Risk Populations' on Dec. 03, 2025.

Brief Summary: This multicenter, prospective, single-arm, interventional study will enroll about 4,000 adult patients at high risk of ATTR amyloidosis from around 50 sites in China. Eligible patients are aged >=60 years and have documented symptomatic heart failure with left ventricular ejection fraction >=40% and LVH. Exclusion criteria include known etiologies of myocardial diseases, anomalies of serum free light chain or serum immunofixation electrophoresis, acute myocardial infarction...